Internship
Software Engineering Intern
Summer 2024
Posted on 11/8/2023
PostEra
11-50 employees
AI-driven solutions for drug discovery
Remote
- Experience in software development outside of the classroom
- Interest in building production-grade software used by chemists and biologists
- Accelerate Medicinal Chemistry using machine learning
- Advance small molecule programs through partnerships with biopharma
- Advance internal pipeline
- Raise funds from investors
- Close AI partnerships
- Launch and lead open-science drug discovery efforts
- Experience in Python development
- Strong statistical and quantitative skills
- Comfort with modern development and deployment tools (Git, Linux, AWS, Docker)
- Application of machine learning to scientific problems
- Academic or professional experience with organic chemistry
- Familiarity with the RDKit library
PostEra.ai focuses on improving the process of drug discovery in the biopharmaceutical industry by using machine learning to speed up the Design-Make-Test cycle of medicinal chemistry. Their technology helps pharmaceutical companies create more effective treatments more quickly than traditional methods. PostEra.ai collaborates with major clients like Amgen and Pfizer, securing over $1 billion in partnerships in the AI drug discovery field. The company operates through strategic collaborations, including a $260 million partnership with Pfizer and a $68 million project funded by the NIH to develop antivirals. By leveraging its advanced machine learning capabilities, PostEra.ai aims to reduce the time and costs associated with drug development, ultimately striving to deliver better cures to patients faster.
Company Stage
Series A
Total Funding
$94.6M
Headquarters
Santa Clara, California
Founded
2019
6 month growth
↑ 9%1 year growth
↑ 5%2 year growth
↑ 89%
Simplify's Take
What believers are saying
- PostEra.ai's collaborations worth over $1 billion in the AI drug discovery space indicate strong financial backing and growth potential.
- The $260 million AI Lab partnership with Pfizer and $68 million NIH-funded antiviral collaboration showcase the company's ability to secure high-value partnerships.
- Recent $24 million Series A financing will enable PostEra.ai to advance its drug discovery programs and potentially bring new cures to market faster.
What critics are saying
- The competitive landscape of AI-driven drug discovery could pose challenges in maintaining a unique market position.
- Dependence on strategic partnerships for revenue generation may expose the company to financial risks if collaborations do not yield expected results.
What makes PostEra unique
- PostEra.ai leverages advanced machine learning to expedite the Design-Make-Test cycle in medicinal chemistry, setting it apart from traditional drug discovery methods.
- The company's strategic partnerships with major pharmaceutical companies like Pfizer and Amgen, along with significant collaborations, highlight its strong market position.
- PostEra.ai's focus on AI-driven drug discovery and development, particularly in antiviral therapeutics, underscores its innovative approach in the biopharmaceutical sector.